Abstract

Herpes simplex virus (HSV) naturally infects skin and mucosal surfaces, causing lifelong recurrent disease worldwide, with no cure or vaccine. Biomimetic human tissue and organ platforms provide attractive alternatives over animal models to recapitulate human diseases. Combining prevascularization and microfluidic approaches, we present a vascularized, three-dimensional skin-on-chip that mimics human skin architecture and is competent to immune-cell and drug perfusion. The endothelialized microvasculature embedded in a fibroblast-containing dermis responds to biological stimulation, while the cornified epidermis functions as a protective barrier. HSV infection of the skin-on-chip displays tissue-level key morphological and pathophysiological features typical of genital herpes infection in humans, including the production of proinflammatory cytokine IL-8, which triggers rapid neutrophil trans-endothelial extravasation and directional migration. Importantly, perfusion with the antiviral drug acyclovir inhibits HSV infection in a dose-dependent and time-sensitive manner. Thus, our vascularized skin-on-chip represents a promising platform for human HSV disease modeling and preclinical therapeutic evaluation.

Understanding host responses to Herpes simplex virus (HSV) in humans is challenging. Here the authors report a vascularised 3D ‘skin-on-chip’ that mimics human skin architecture and is competent to immune-cell and drug perfusion; they use this to model HSV infection.

Details

Title
Modeling human HSV infection via a vascularized immune-competent skin-on-chip platform
Author
Sun, Sijie 1 ; Jin, Lei 2 ; Zheng, Ying 3   VIAFID ORCID Logo  ; Zhu, Jia 4   VIAFID ORCID Logo 

 University of Washington School of Medicine, Department of Laboratory Medicine and Pathology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622) 
 Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622) 
 University of Washington, Department of Bioengineering, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Institute of Stem Cell and Regenerative Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657) 
 University of Washington School of Medicine, Department of Laboratory Medicine and Pathology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622); University of Washington, Institute of Stem Cell and Regenerative Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2715621437
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.